ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
PAVmed Inc

PAVmed Inc (PAVM)

0.64
-0.008
( -1.23% )
更新日時: 23:54:04

個人投資家向けのプロ仕様のツール。

主要統計と詳細

通貨
0.64
買値
0.621
売値
0.6466
出来高
10,254
0.625861 日の範囲 0.648
0.5719 52 週間の範囲 3.50
時価総額
前日終値
0.648
始値
0.64
最終取引時間
23:56:24
財務取引量
US$ 6,488
VWAP
0.632765
平均取引量 (3 か月)
175,926
発行済株式数
11,068,566
配当利回り
-
PER
-0.11
1 株当たり利益 (EPS)
-5.99
歳入
2.45M
純利益
-66.27M

PAVmed Inc について

PAVmed Inc is a medical device company engaged in advancing a pipeline of medical technologies from concept to commercialization using a business model focused on capital and time efficiency. Its product includes EsoCheck; CarpX; EsoGuard; PortIO; DisappEAR and others. PAVmed Inc is a medical device company engaged in advancing a pipeline of medical technologies from concept to commercialization using a business model focused on capital and time efficiency. Its product includes EsoCheck; CarpX; EsoGuard; PortIO; DisappEAR and others.

セクター
Surgical,med Instr,apparatus
業界
Surgical,med Instr,apparatus
ウェブサイト
本社
Wilmington, Delaware, USA
設立
-
PAVmed Inc is listed in the Surgical,med Instr,apparatus sector of the ナスダック市場 with ticker PAVM. The last closing price for PAVmed was US$0.65. Over the last year, PAVmed shares have traded in a share price range of US$ 0.5719 to US$ 3.50.

PAVmed currently has 11,068,566 shares in issue. The market capitalisation of PAVmed is US$7.17 million. PAVmed has a price to earnings ratio (PE ratio) of -0.11.

PAVM 最新ニュース

Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume

Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume PR Newswire NEW YORK, Jan. 13, 2025 Quarterly test volume of over 4,000 tests represented sequential increase of 45 percent NEW...

Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule PR Newswire NEW YORK, Dec. 23, 2024 NEW YORK, Dec. 23, 2024 /PRNewswire/ -- Lucid...

Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters

Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters PR Newswire NEW YORK, Dec. 19, 2024 Partnership launched with fully-contracted...

Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication

Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication PR Newswire NEW YORK, Dec. 11, 2024 Study demonstrates outstanding...

Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones

Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones PR Newswire NEW YORK, Dec. 3, 2024 New convertible debt...

Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test

Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test PR Newswire NEW YORK, Nov. 20, 2024 NEW YORK, Nov. 20, 2024 /PRNewswire/...

Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum PR Newswire NEW YORK, Nov. 18, 2024 NEW YORK, Nov. 18, 2024 /PRNewswire/...

PAVmed Provides Business Update and Third Quarter 2024 Financial Results

PAVmed Provides Business Update and Third Quarter 2024 Financial Results PR Newswire NEW YORK, Nov. 14, 2024 Lucid reports record quarterly EsoGuard® revenue and completes clinical evidence...

Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication

Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication PR Newswire NEW YORK, Nov. 7...

Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers

Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers PR Newswire NEW YORK, Nov. 5, 2024 Industry veterans from leading cancer...

期間 †前日比前日比 %始値高値安値平均出来高VWAP
1-0.019-2.883156297420.6590.680.57192451490.63644287CS
4-0.03-4.47761194030.670.760.57192453480.64694591CS
12-0.39-37.86407766991.031.250.57191759260.74165328CS
26-0.36-3611.90.57191123440.87287307CS
52-1.69-72.53218884122.333.50.5719888221.20982396CS
156-22.76-97.26495726523.435.10.571958073014.05860404CS
260-21.56-97.117117117122.2145.50.5719114811247.88176448CS

PAVM - Frequently Asked Questions (FAQ)

What is the current PAVmed share price?
The current share price of PAVmed is US$ 0.64
How many PAVmed shares are in issue?
PAVmed has 11,068,566 shares in issue
What is the market cap of PAVmed?
The market capitalisation of PAVmed is USD 7.17M
What is the 1 year trading range for PAVmed share price?
PAVmed has traded in the range of US$ 0.5719 to US$ 3.50 during the past year
What is the PE ratio of PAVmed?
The price to earnings ratio of PAVmed is -0.11
What is the cash to sales ratio of PAVmed?
The cash to sales ratio of PAVmed is 2.93
What is the reporting currency for PAVmed?
PAVmed reports financial results in USD
What is the latest annual turnover for PAVmed?
The latest annual turnover of PAVmed is USD 2.45M
What is the latest annual profit for PAVmed?
The latest annual profit of PAVmed is USD -66.27M
What is the registered address of PAVmed?
The registered address for PAVmed is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the PAVmed website address?
The website address for PAVmed is www.pavmed.com
Which industry sector does PAVmed operate in?
PAVmed operates in the SURGICAL,MED INSTR,APPARATUS sector

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
GITSGlobal Interactive Technologies Inc
US$ 1.979
(1,933.92%)
13.94k
JGAurora Mobile Ltd
US$ 17.675
(193.99%)
16.99M
AKROAkero Therapeutics Inc
US$ 54.55
(108.37%)
6.95M
ONCOOnconetix Inc
US$ 0.8509
(77.27%)
108.79M
YIBOPlanet Image International Ltd
US$ 3.60
(67.44%)
45.55k
ALLKAllakos Inc
US$ 0.2903
(-76.01%)
15.08M
VERUVeru Inc
US$ 0.699
(-42.23%)
17.01M
ELABPMGC Holdings Inc
US$ 1.9575
(-36.85%)
2.06M
NXUNXU Inc
US$ 0.3968
(-35.58%)
1.95M
NBISNebius Group NV
US$ 30.0097
(-28.02%)
10.22M
NVDANVIDIA Corporation
US$ 126.8791
(-11.04%)
150.45M
HOLOMicroCloud Hologram Inc
US$ 2.05
(32.26%)
120.85M
ONCOOnconetix Inc
US$ 0.8509
(77.27%)
108.79M
HWHHWH International Inc
US$ 0.4384
(52.38%)
60.42M
MLGOMicroAlgo Inc
US$ 2.0303
(33.57%)
53.01M

PAVM Discussion

投稿を表示